Researchers Call for Expansion of Mint Tobacco Ban

Dec.08.2022
Researchers Call for Expansion of Mint Tobacco Ban
Researchers urge FDA to expand ban on mint-flavored tobacco products to include potential substitutes like mint pipes and cigarillos.

Researchers from the Rutgers Tobacco Research Center and Ohio State University are calling for the US Food and Drug Administration (FDA) to expand the ban on mint-flavored cigarettes and cigars to include potential alternatives like mint-flavored pipes and rolling papers.


According to a study published in the journal Tobacco Control, researchers are urging the FDA to maximize the benefits of the ban on menthol-flavored cigarettes based on new evidence showing that these alternatives are attractive and have the potential to be addictive for adults who smoke menthol cigarettes.


Andrea Villanti, Associate Director of the Rutgers University Tobacco Research Center, stated that tobacco companies have renamed their roll-your-own tobacco as pipe tobacco to avoid taxes, and have branded flavored cigarettes as flavored cigars to evade federal bans. Villanti, the lead researcher of the study, said, "We have seen companies promoting pipe tobacco and cigarillos alongside cigarettes and filtered cigars. The products we tested in our research are likely the ones tobacco companies will promote after mint-flavored cigarettes are banned.


Researchers examined 98 adults who smoked menthol cigarettes to compare the addictive potential of combustible menthol with its substitutes. The study was conducted in four parts over a three-week period, during which participants first smoked their usual brand of menthol cigarettes. In the next three sessions, participants were randomly assigned three different menthol cigarette substitutes:


One cigarette that does not contain menthol alcohol is a pre-assembled menthol cigarette made with mint tobacco and a menthol pipe for filtering. It also includes a small menthol cigar.


During each meeting, researchers measured the smoking habits of participants, including the amount of carbon monoxide emitted, cravings, and withdrawal symptoms. Participants also self-reported their perceived effects of the drug and evaluated other measures of addiction potential for each product.


The team discovered that while menthol-filtered small cigars and non-mentholated cigarettes are attractive alternatives to menthol cigarettes, menthol pipe tobacco and rolling papers are the most alluring and lead to the highest number of indicators for future nicotine addiction. However, these products have not been considered for inclusion in the proposed ban.


According to the investigation results, the components of menthol cigarette products, including menthol paper, cigarette tube, and tobacco for pipe, should be included in the standards for menthol cigarettes and flavored cigars, as stated by Villanti.


Previous research has established a correlation between the use of menthol-flavored cigarettes and an increase in smoking initiation, nicotine dependence, and reduced adult smoking cessation, particularly among vulnerable populations. The FDA has proposed a regulation prohibiting the use of menthol as a flavoring agent in cigarettes and cigars to address this public health concern. Following a review of public feedback, a final decision is expected to be made in the coming months.


Currently, research results indicate that the components of menthol cigarette products, including menthol cigarette paper, filters, and tobacco, should be included in the standards for menthol cigarettes and flavored cigars," said Theodore Wagener, director of the center. The research was conducted by the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and the lead author of the study. "Failing to comply with this restriction would result in a serious loophole that the tobacco industry has already exploited and could potentially weaken the potential public health benefits of the proposed menthol ban.


2FIRSTS will continue to provide ongoing coverage of this topic, with further updates available on the "2FIRSTSAPP" platform. Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
FOGER has introduced the Switch Pro 30K Nixodine Pod in U.S. retail channels, bringing a 6-methylnicotine (6-MN)-related formulation into its reusable Switch Pro 30K pod ecosystem. The product retains the existing reusable dock and magnetic replacement pod architecture, featuring a 19ml prefilled pod, dual-mesh heating and Normal/Boost modes. The Nixodine version is labeled nicotine-free in terms of conventional nicotine but uses a 5% Nixodine-related formulation. The product has appeared in U.S. retail and wholesale channels, with some listings indicating Kentucky-only availability.
Aug.28
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
BAT CFO Dragos Constantinescu Takes Office, Returning After Seven Years and Former Asahi Europe Leadership Role
BAT CFO Dragos Constantinescu Takes Office, Returning After Seven Years and Former Asahi Europe Leadership Role
Dragos Constantinescu has officially taken up his role as Chief Financial Officer and Executive Director at British American Tobacco (BAT). He previously spent 16 years at BAT across finance and general management roles in Europe before joining Asahi in 2019 and becoming CEO of Asahi Europe & International in 2025. His return comes as BAT continues to advance its “A Better Tomorrow” transformation.
BAT
Sep.01
SMOORE’s DOJO by VAPORESSO to Launch New Global Brand Identity on September 1
SMOORE’s DOJO by VAPORESSO to Launch New Global Brand Identity on September 1
According to recent LinkedIn posts from people at VAPORESSO, SMOORE and a German distribution partner, vape brand DOJO will begin rolling out a new global brand identity on September 1, 2026, led by a redesigned handwritten logo. The new visual system will be gradually applied across product packaging, marketing materials and digital assets over the following months. Fabio Corsaro, Head of Marketing and Purchasing at MG Wesel GmbH, said the rebrand was related to trademark issues, but that explanation has not been publicly confirmed by DOJO, VAPORESSO or SMOORE. DOJO is currently promoting its Blast X product in Germany.
Aug.31
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
Following recent FDA authorizations for JUUL2 and ZYN ULTRA, 2Firsts Compliance Solutions held an online PMTA briefing on Sept. 4 to examine what the decisions may signal about review efficiency, scientific evidence and U.S. market access. Nearly 30 participants from brands, manufacturers, compliance service providers and investment firms joined the discussion.
2Firsts Events
Sep.06
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives